MHC Class I Antigens In Malignant Cells (Record no. 44660)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 03680nam a22005177a 4500 |
001 - CONTROL NUMBER | |
control field | sulb-eb0022568 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | BD-SySUS |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20160413122306.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 130228s2013 xxu| s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9781461465430 |
-- | 978-1-4614-6543-0 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1007/978-1-4614-6543-0 |
Source of number or code | doi |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | RC261-271 |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MJCL |
Source | bicssc |
Subject category code | MED062000 |
Source | bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 614.5999 |
Edition number | 23 |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Aptsiauri, Natalia. |
Relator term | author. |
245 10 - TITLE STATEMENT | |
Title | MHC Class I Antigens In Malignant Cells |
Medium | [electronic resource] : |
Remainder of title | Immune Escape And Response To Immunotherapy / |
Statement of responsibility, etc. | by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Place of production, publication, distribution, manufacture | New York, NY : |
Name of producer, publisher, distributor, manufacturer | Springer New York : |
-- | Imprint: Springer, |
Date of production, publication, distribution, manufacture, or copyright notice | 2013. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | VIII, 51 p. 17 illus., 14 illus. in color. |
Other physical details | online resource. |
336 ## - CONTENT TYPE | |
Content type term | text |
Content type code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media type term | computer |
Media type code | c |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier type term | online resource |
Carrier type code | cr |
Source | rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS | |
File type | text file |
Encoding format | |
Source | rda |
490 1# - SERIES STATEMENT | |
Series statement | SpringerBriefs in Cancer Research ; |
Volume/sequential designation | 6 |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion. |
520 ## - SUMMARY, ETC. | |
Summary, etc. | Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. . |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Medicine. |
Topical term or geographic name as entry element | Cancer research. |
Topical term or geographic name as entry element | Immunology. |
Topical term or geographic name as entry element | Molecular biology. |
Topical term or geographic name as entry element | Biomedicine. |
Topical term or geographic name as entry element | Cancer Research. |
Topical term or geographic name as entry element | Immunology. |
Topical term or geographic name as entry element | Molecular Medicine. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Garcia-Lora, Angel Miguel. |
Relator term | author. |
Personal name | Cabrera, Teresa. |
Relator term | author. |
710 2# - ADDED ENTRY--CORPORATE NAME | |
Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY | |
Title | Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Relationship information | Printed edition: |
International Standard Book Number | 9781461465423 |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | SpringerBriefs in Cancer Research ; |
Volume number/sequential designation | 6 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="http://dx.doi.org/10.1007/978-1-4614-6543-0">http://dx.doi.org/10.1007/978-1-4614-6543-0</a> |
912 ## - | |
-- | ZDB-2-SBL |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Source of classification or shelving scheme | |
Koha item type |
No items available.